Aurora Cannabis Inc.

ACB Healthcare Drug Manufacturers Specialty & Generic

Aurora Cannabis Inc.’s revenue for fiscal 2026 (year ended March 2026) was $232.0 million, down 5.95% from fiscal 2025. In the quarter to June 2026, revenue fell 31.2%, EPS grew 75.0%, free cash flow fell 293.6% and total debt fell 82.5%, each against the same quarter a year earlier.

3.99 0.11 −2.68%
Market cap
$265.8M
P/E
0.0×
Fwd P/E
−783×
Dividend yield
—
F-score
4/9
Altman Z
−12.34
Beneish M
−2.53
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
Piotroski F-Score

+8 more TTM periods

4 3 4 4
ROE
(10.17%) (15.13%) (21.82%) (19.85%)
ROA
(7.47%) (10.88%) (16.82%) (15.19%)
ROIC
(3.88%) (8.26%) (7.98%) (5.58%)
Return on Tangible Assets
(10.46%) (15.94%) (26.81%) (23.74%)
Average Days of Receivables
47.12 43.27 50.75 51.59
Free Cash Flow per Share
(0.21) (0.37) (0.45) (0.59)
Free Cash Flow
(12.09) (21.26) (25.30) (36.10)
Other line items

Show all line items

Columns are period end dates